Matsuno H, et al. - Herein the researchers assessed the similarities between LBEC0101 (etanercept biosimilar) and the etanercept reference product (ETN-RP) in terms of effectiveness and safety, including immunogenicity, in subjects with active rheumatoid arthritis despite methotrexate treatment. They noted the clinical efficacy of LBEC0101 and ETN-RP to be equal. LBEC0101 was well tolerated and had a comparable safety profile to ETN-RP.